BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27246906)

  • 1. Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
    Ponder KG; Matulis SM; Hitosugi S; Gupta VA; Sharp C; Burrows F; Nooka AK; Kaufman JL; Lonial S; Boise LH
    Cancer Biol Ther; 2016 Jul; 17(7):769-77. PubMed ID: 27246906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
    Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
    Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
    Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
    Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
    Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
    Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells.
    Pallis M; Burrows F; Ryan J; Grundy M; Seedhouse C; Abdul-Aziz A; Montero J; Letai A; Russell N
    Oncotarget; 2017 Mar; 8(10):16220-16232. PubMed ID: 27092880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical review on carfilzomib in multiple myeloma.
    Muchtar E; Gertz MA; Magen H
    Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
    Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
    [No Abstract]   [Full Text] [Related]  

  • 11. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo.
    Jarauta V; Jaime P; Gonzalo O; de Miguel D; Ramírez-Labrada A; Martínez-Lostao L; Anel A; Pardo J; Marzo I; Naval J
    Cancer Lett; 2016 Nov; 382(1):1-10. PubMed ID: 27565383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition.
    Le Rhun E; von Achenbach C; Lohmann B; Silginer M; Schneider H; Meetze K; Szabo E; Weller M
    Int J Cancer; 2019 Jul; 145(1):242-253. PubMed ID: 30549269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
    Fan F; Tonon G; Bashari MH; Vallet S; Antonini E; Goldschmidt H; Schulze-Bergkamen H; Opferman JT; Sattler M; Anderson KC; Jäger D; Podar K
    Cancer Lett; 2014 Feb; 343(2):286-94. PubMed ID: 24120758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway.
    Tong J; Yu Q; Xu W; Yu W; Wu C; Wu Y; Yan H
    Cancer Biol Ther; 2019; 20(3):381-390. PubMed ID: 30359543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.
    Goh KC; Novotny-Diermayr V; Hart S; Ong LC; Loh YK; Cheong A; Tan YC; Hu C; Jayaraman R; William AD; Sun ET; Dymock BW; Ong KH; Ethirajulu K; Burrows F; Wood JM
    Leukemia; 2012 Feb; 26(2):236-43. PubMed ID: 21860433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.
    Boccon-Gibod C; Talbot A; Le Bras F; Frenzel L; Royer B; Harel S; Lombion N; Belhadj K; Cuccuini W; Arnulf B
    Br J Haematol; 2020 May; 189(3):e73-e76. PubMed ID: 32012229
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways.
    Lei L; Zhang Y; Jian Q; Lei L; Lv N; Williamson RA; Chen P; Zhang D; Hu J
    Exp Physiol; 2021 Feb; 106(2):438-449. PubMed ID: 33336554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.